The lap band gastric banding system — more accurately described as a laparoscopic adjustable gastric band (LAGB) — is a minimally invasive bariatric procedure designed to help adults with obesity achieve sustained weight loss. A silicone band is placed around the upper stomach, creating a small pouch that limits food intake. Unlike gastric bypass or sleeve gastrectomy, the band does not permanently alter the digestive tract and can be adjusted or removed. This article explains how the procedure works, who qualifies for NHS treatment, the associated risks, post-operative care, and the alternatives currently available in the UK.

What Is the Lap-Band Gastric Banding System?

LAGB is a minimally invasive procedure placing an adjustable silicone band around the upper stomach to restrict food intake; it is reversible and does not permanently alter the digestive tract.

The term 'Lap-Band' is a registered trademark for one brand of laparoscopic adjustable gastric band (LAGB); several other devices are available in the UK. This article uses the generic terms 'gastric band' and 'LAGB' throughout. The procedure involves placing an adjustable silicone band around the upper portion of the stomach, creating a small pouch above the band that limits the amount of food a person can comfortably consume at one time. The operation is performed laparoscopically — through small incisions using a camera and surgical instruments — making it minimally invasive compared with open surgery.

The band is connected via a thin tube to a small port implanted just beneath the skin, usually on the abdominal wall. A healthcare professional can inject saline solution through this port to tighten or loosen the band, adjusting the degree of restriction to suit the individual patient's needs and progress. This adjustability is one of the key distinguishing features of LAGB compared with other bariatric procedures.

Unlike gastric bypass or sleeve gastrectomy, LAGB does not involve cutting or permanently altering the stomach or digestive tract. It works primarily by restricting food intake rather than altering nutrient absorption. Patients typically feel full more quickly and for longer periods, which — when combined with dietary and lifestyle changes — can support sustained weight loss over time. On average, patients may lose around 40–60% of their excess body weight, though results vary considerably between individuals and tend to be less durable than those achieved with sleeve gastrectomy or gastric bypass. The procedure is reversible, as the band can be removed if necessary, though this does not guarantee the stomach will return to its original function.

For further information on the procedure, see the NHS weight loss surgery page (NHS.UK).

Who Is Eligible for Gastric Banding on the NHS?

NICE guideline CG189 recommends bariatric surgery for adults with a BMI of 40 kg/m² or above, or 35–39.9 kg/m² with a significant obesity-related condition, after non-surgical interventions have failed.

Access to gastric banding on the NHS is guided by criteria set out by the National Institute for Health and Care Excellence (NICE). According to NICE guidance (CG189), bariatric surgery — including gastric banding — is typically considered for adults who meet the following criteria:

• A body mass index (BMI) of 40 kg/m² or above, or

• A BMI of 35–39.9 kg/m² alongside a significant obesity-related condition such as type 2 diabetes, hypertension, or obstructive sleep apnoea

• All appropriate non-surgical weight management interventions have been tried and have not achieved or maintained clinically beneficial weight loss

• The individual is fit for anaesthesia and surgery

• The individual commits to long-term follow-up

NICE also recommends that people with a BMI of 30–34.9 kg/m² who have recent-onset type 2 diabetes may be considered for surgery in some circumstances. Expedited assessment may be offered to people with a BMI over 50 kg/m².

Eligibility is assessed within specialist Tier 3 or Tier 4 weight management services, in line with local NHS commissioning policies. Decisions are made by a multidisciplinary team (MDT) that includes a bariatric surgeon, dietitian, psychologist, and specialist nurse. Referral is usually initiated through a GP, who will assess suitability and refer to a specialist weight management service.

It is important to note that NHS availability of gastric banding specifically has become more limited in recent years. Data from the National Bariatric Surgery Registry (NBSR) show that many NHS trusts now favour sleeve gastrectomy or gastric bypass, which tend to produce greater and more durable weight loss with lower long-term complication and revision rates. The lower BMI thresholds applicable to some pharmacotherapies do not automatically apply to surgical referral.

Risks, Complications and Long-Term Considerations

LAGB carries risks including band slippage, band erosion, port problems, and oesophageal dilation; up to 40–50% of patients require revision or removal within ten years.

As with any surgical procedure, LAGB carries both short-term and long-term risks. Patients should be fully informed of these before consenting to surgery. Short-term surgical risks include:

• Infection at the port or incision sites

• Bleeding or adverse reactions to anaesthesia

• Blood clots (deep vein thrombosis or pulmonary embolism), though these are mitigated by prophylactic measures

Longer-term complications are more specific to the device itself and are an important consideration. These include:

• Band slippage, where the stomach slips through the band, causing obstruction or reflux

• Band erosion, in which the band gradually wears through the stomach wall — a serious complication requiring surgical removal

• Port or tubing problems, such as leaks, flipping of the port, or disconnection

• Oesophageal dilation, where the oesophagus widens over time due to repeated obstruction

• Inadequate weight loss or weight regain, which is more common with banding than with other bariatric procedures

Long-term follow-up data, including UK NBSR reports and large cohort studies, suggest that a significant proportion of patients — with some estimates of up to 40–50% over ten years — require band removal or revision surgery. This has contributed to a decline in the use of gastric banding in the UK.

When to seek urgent medical attention Patients should contact their surgical team promptly — or attend A&E if symptoms are severe — if they experience any of the following, as these may indicate a complication requiring urgent assessment:

• Persistent or bilious vomiting, or inability to tolerate liquids

• Severe abdominal pain

• Fever or signs of infection

• Rapid heart rate (tachycardia)

• Chest pain or breathlessness (which may indicate pulmonary embolism)

• Severe difficulty swallowing or pain around the port site

Patients who experience prolonged or repeated vomiting are at risk of thiamine (vitamin B1) deficiency, which can cause serious neurological complications (including Wernicke's encephalopathy). Urgent medical review and early thiamine supplementation should be sought if vomiting is protracted.

Suspected problems with the device should also be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Life After Gastric Band Surgery: Diet and Follow-Up Care

Post-operative care involves a structured dietary progression, regular band adjustments, annual blood tests per BOMSS guidance, and long-term multivitamin supplementation.

Recovery from LAGB is generally quicker than from more invasive bariatric procedures, with most patients discharged within one to two days. However, the post-operative period requires careful dietary management and ongoing commitment to lifestyle change to achieve meaningful and sustained weight loss.

In the weeks immediately following surgery, patients progress through a structured dietary plan:

• Weeks 1–2: Liquid diet only (water, thin soups, protein shakes)

• Weeks 3–4: Pureed or soft foods

• Week 5 onwards: Gradual reintroduction of solid foods, with careful attention to portion sizes and eating pace

Patients are advised to eat slowly, chew food thoroughly, avoid drinking fluids with meals, and stop eating as soon as they feel full. Eating too quickly or consuming foods that are too dense can cause discomfort, vomiting, or band slippage. High-calorie liquid foods such as milkshakes or alcohol can bypass the restriction and undermine weight loss — a phenomenon sometimes called 'eating around the band'. Minimising alcohol intake and stopping smoking are strongly recommended, as both can increase the risk of complications and impair long-term outcomes.

Nutritional monitoring and supplementation Regular follow-up appointments are essential. These typically involve band adjustments (fills or unfills), dietary reviews with a specialist dietitian, and monitoring of nutritional status. In line with British Obesity and Metabolic Surgery Society (BOMSS) guidance, routine blood tests should include full blood count (FBC), ferritin, vitamin B12, folate, vitamin D, calcium, parathyroid hormone (PTH), and urea, electrolytes, and liver function tests (U&E/LFTs), at intervals determined by local protocols (typically at 3, 6, and 12 months post-operatively, then annually). Patients are usually advised to take a complete daily multivitamin and mineral supplement long-term; additional iron, vitamin B12, and vitamin D or calcium supplementation may be required based on blood test results.

Pregnancy planning Patients who are planning a pregnancy should discuss this with their bariatric team. It is generally recommended to delay conception for at least 12–18 months after surgery. Band adjustment (deflation) during pregnancy may be considered to ensure adequate nutritional intake; appropriate contraception should be discussed prior to surgery and during the post-operative period.

Psychological support may also be offered, as addressing the behavioural and emotional aspects of eating is central to long-term success.

Alternatives to Gastric Banding Available in the UK

Sleeve gastrectomy and Roux-en-Y gastric bypass are the most commonly performed NHS alternatives, offering greater and more durable weight loss than gastric banding.

For patients who are considering bariatric surgery or who have been declined gastric banding, several alternative procedures are available in the UK, both on the NHS and privately. The most commonly performed options include:

Sleeve gastrectomy involves the surgical removal of approximately 75–80% of the stomach, leaving a narrow, sleeve-shaped tube. It is now one of the most frequently performed bariatric procedures in the UK, offering significant and durable weight loss with a lower rate of long-term complications compared with gastric banding, though it is not reversible.

Roux-en-Y gastric bypass is considered the gold-standard bariatric procedure for many patients. It involves creating a small stomach pouch and rerouting the small intestine, thereby both restricting food intake and reducing nutrient absorption. It is particularly effective for patients with type 2 diabetes and tends to produce greater weight loss than banding, though it carries its own nutritional and surgical risks.

Intragastric balloon is a non-surgical, temporary option in which a saline-filled balloon is placed in the stomach endoscopically, typically for up to six months. It may be suitable for patients who do not yet meet the threshold for surgery or who wish to lose weight before a planned procedure. It requires structured dietary follow-up and is not a permanent solution; UK guidance should be consulted for current indications.

Tier 3 and Tier 4 weight management programmes on the NHS provide structured, non-surgical interventions including dietary counselling, behavioural therapy, and pharmacological support. Orlistat, which is licensed in the UK for weight management (see the BNF or the MHRA-approved Summary of Product Characteristics for full prescribing information, including indications and contraindications), may be offered as part of a comprehensive weight management plan. Semaglutide 2.4 mg (Wegovy) received a positive NICE technology appraisal (TA875) in 2023 for weight management in adults with a BMI of 35 kg/m² or above (or 30–34.9 kg/m² in certain circumstances) alongside at least one weight-related comorbidity. It is indicated for use within specialist NHS weight management services, for a time-limited period, and in conjunction with a reduced-calorie diet and increased physical activity. Access may be subject to local commissioning constraints and service capacity.

Suspected side effects from any medicine should be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Patients should discuss all available options with their GP or specialist team to determine the most appropriate pathway based on their individual health profile, preferences, and clinical needs.

Frequently Asked Questions